Health
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
WILMINGTON, Del., March 09, 2026--AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment.
About this update from Astrazeneca Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1181,"height":286,"url":"https://media.zenfs.com/en/business-wire.com/ded2f77c199681a2d6bc86ca88abffa5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/funkLcPuivqr62du_CamAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ded2f77c199681a2d6bc86ca88abffa5","width":960,"height":232},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/E2Euq_PVCyx9.3U_1cVKyA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIzNjI7aD01NzI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/ded2f77c199681a2d6bc86ca88abffa5","width":1181,"height":286}},"lazy":false},{"type":"text","content":"Based on DESTINY-Breast05 Phase III trial results which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared with T-DM1","length":154,"tagName":"p","attribs":{}},{"type":"text","content":"If approved, AstraZeneca and Daiichi Sankyo’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting","length":140,"tagName":"p","attribs":{}},{"type":"text","content":"WILMINGTON, Del., March 09, 2026--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment.","length":383,"tagName":"p"},{"type":"text","content":"The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available treatment options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance. The Prescription Drug User Fee Act date, the FDA action date for its regulatory decision, is anticipated during the third quarter of 2026.","length":432,"tagName":"p"},{"type":"text","content":"ENHERTU was recently granted Breakthrough Therapy Designation (BTD) by the FDA in this setting. BTD accelerates the development and regulatory review of potential new medicines intended to treat a serious condition and address a significant unmet medical need.","leng...